Cargando…
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study
This is one of the few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in brain cancer patients. Baseline HRQOL scores (from the EORTC QLQ-C30 and the Brain Cancer Module (BN 20)) were examined in 490 newly diagnosed gliobla...
Autores principales: | Mauer, M, Stupp, R, Taphoorn, M J B, Coens, C, Osoba, D, Marosi, C, Wong, R, de Witte, O, Cairncross, J G, Efficace, F, Mirimanoff, R O, Forsyth, P, van den Bent, M J, Weller, M, Bottomley, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360328/ https://www.ncbi.nlm.nih.gov/pubmed/17609661 http://dx.doi.org/10.1038/sj.bjc.6603876 |
Ejemplares similares
-
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
por: Baumert, Brigitta G., et al.
Publicado: (2016) -
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
por: Dirven, Linda, et al.
Publicado: (2021) -
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial
por: Ediebah, D E, et al.
Publicado: (2014) -
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
por: Stupp, R., et al.
Publicado: (2011) -
Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)